Adrienne G. Waks

Harvard University — United States

Medicine · Health Sciences

22h-index8.3kcitations215works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(88), Breast Cancer Treatment Studies(86), HER2/EGFR in Cancer Research(67), Cancer Treatment and Pharmacology(59), Cancer Genomics and Diagnostics(37)

Publications214 total

The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS)
npj Breast Cancer·2026Open Access
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer
Nature Communications·2025· 2 citedOpen Access
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
Nature Communications·2025· 1 citedOpen Access
1270 APOE tumor-associated macrophages and CD4-DOCK4 T cells reveal distinct microenvironmental features in HER2-Low and HER2–0 hormone receptor-positive breast cancer
Regular and Young Investigator Award Abstracts·2025Open Access
APOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer
2025Open Access
Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot study
Breast Cancer Research and Treatment·2025· 2 cited
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
JNCI Journal of the National Cancer Institute·2025· 4 cited
TRLS-09 CEREBROSPINAL FLUID (CSF) AND PLASMA CIRCULATING TUMOR DNA (CTDNA) FOR MOLECULAR PROFILING AND MONITORING OF TREATMENT RESPONSE IN A PHASE II TRIAL OF PAXALISIB FOR HER2-POSITIVE (HER2+) BREAST CANCER BRAIN METASTASES (BCBM)
Neuro-Oncology Advances·2025Open Access
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
The Lancet Oncology·2025· 11 cited
Abstract P2-10-20: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)
Clinical Cancer Research·2025
Abstract LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer
Clinical Cancer Research·2025· 1 cited
Abstract P5-08-11: Comprehensive characterization of the immune landscape in HER2-low and HER2-0 hormone receptor positive tumors
Clinical Cancer Research·2025
AXALAP: Phase Ib study of axatilimab in combination with olaparib in <i>BRCA1/2</i> and <i>PALB2</i> -associated metastatic HER2-negative breast cancer (BC).
Journal of Clinical Oncology·2025
A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.
Journal of Clinical Oncology·2025· 1 cited
Abstract CT028: A single-arm phase 1 trial of avutometinib (RAF/MEK inhibitor), abemaciclib (abema), and fulvestrant in CDK4/6 inhibitor (CDK4/6i)-pretreated patients (pts) with HR+ metastatic breast cancer (MBC)
Cancer Research·2025
Abstract 1172: An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer
Cancer Research·2025
122 Clinical and Histological Characteristics of pT1miN0 HER2-Positive (HER2+) Breast Cancer Patients Who Did Versus Did Not Experience Recurrence: A Single-Institution Case Series
Laboratory Investigation·2025Open Access
176 Machine Learning-Enabled Pathological Features of Post-Preoperative Therapy Surgical Specimens Improves Recurrence Prediction in Patients with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NAC)
Laboratory Investigation·2025Open Access
An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer
2024· 1 citedOpen Access
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy
Cancer Treatment Reviews·2024· 12 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Eric P. Winer(32), Sara M. Tolaney(31), Ian E. Krop(19), Nancy U. Lin(15), Elizabeth A. Mittendorf(14), Nabihah Tayob(13), Nikhil Wagle(12), Paolo Tarantino(11), Ofir Cohen(10), Ann H. Partridge(10), Seth A. Wander(9), Tari A. King(9), Karla Helvie(8), Denise A. Yardley(8), Laura M. Spring(8), Aleix Prat(8), Samuel S. Freeman(7), Otto Metzger(7), Meredith Faggen(7), Utthara Nayar(6)